胰岛素德谷门冬双胰岛素：首个胰岛素类似物复方制剂
Insulin Degludec Aspart: The First Co-formulation of Insulin Analogues.
机构信息
Department of Endocrinology, Bharti Hospital and BRIDE, Karnal, 132001, Haryana, India,
出版信息
Diabetes Ther. 2014 Jun;5(1):65-72. doi: 10.1007/s13300-014-0067-x. Epub 2014 May 15.
Abstract
Insulin degludec/insulin aspart (IDegAsp) is the first soluble co-formulation which combines two insulin analogues, and provides effective basal and prandial glycemic coverage. It has been assessed as basal insulin in type 2 diabetes mellitus (T2DM), and as part of basal-bolus regime in both type 1 diabetes mellitus and T2DM. Insulin degludec has also been assessed as flexibly administered basal insulin in terms of time of administration. This review discusses data pertaining to the efficacy, safety, tolerability, and clinical potential of IDegAsp. The discussion includes comparisons of IDegAsp with basal as well as premixed insulin.
摘要
德谷胰岛素/门冬胰岛素（IDegAsp）是首个可溶性的双胰岛素复方制剂，它结合了两种胰岛素类似物，可有效控制基础和餐时血糖。该药已被评估为用于 2 型糖尿病（T2DM）的基础胰岛素，也被评估为 1 型糖尿病和 T2DM 的基础-餐时胰岛素方案中的基础胰岛素部分。此外，该药还被评估为可灵活给药的基础胰岛素，给药时间较为灵活。本综述讨论了 IDegAsp 的疗效、安全性、耐受性和临床潜力的数据。讨论内容包括 IDegAsp 与基础胰岛素和预混胰岛素的比较。
相似文献
1
Insulin Degludec Aspart: The First Co-formulation of Insulin Analogues.胰岛素德谷门冬双胰岛素：首个胰岛素类似物复方制剂
Diabetes Ther. 2014 Jun;5(1):65-72. doi: 10.1007/s13300-014-0067-x. Epub 2014 May 15.
2
Pragmatic use of insulin degludec/insulin aspart co-formulation: A multinational consensus statement.德谷胰岛素/门冬胰岛素共混制剂的实用应用：一项跨国共识声明。
Indian J Endocrinol Metab. 2016 Jul-Aug;20(4):542-5. doi: 10.4103/2230-8210.182980.
3
Clinical use of the co-formulation of insulin degludec and insulin aspart.德谷胰岛素与门冬胰岛素复方制剂的临床应用
Int J Clin Pract. 2016 Aug;70(8):657-67. doi: 10.1111/ijcp.12821. Epub 2016 Jul 7.
4
Insulin degludec/insulin aspart in Japanese patients with type 1 diabetes mellitus: Distinct prandial and basal glucose-lowering effects.德谷胰岛素/门冬胰岛素用于日本1型糖尿病患者：独特的餐时和基础降糖作用
J Diabetes Investig. 2016 Jul;7(4):574-80. doi: 10.1111/jdi.12461. Epub 2016 Feb 4.
5
Distinct Prandial and Basal Glucose-Lowering Effects of Insulin Degludec/Insulin Aspart (IDegAsp) at Steady State in Subjects with Type 1 Diabetes Mellitus.在 1 型糖尿病患者中，德谷胰岛素/门冬胰岛素（IDegAsp）在稳态下具有不同的餐时和基础降糖作用。
Diabetes Ther. 2014 Jun;5(1):255-65. doi: 10.1007/s13300-014-0070-2. Epub 2014 Jun 3.
6
Use of Insulin Degludec/Insulin Aspart in the Management of Diabetes Mellitus: Expert Panel Recommendations on Appropriate Practice Patterns.德谷胰岛素/门冬胰岛素在糖尿病管理中的应用：专家小组关于适当实践模式的建议。
Front Endocrinol (Lausanne). 2021 Mar 12;12:616514. doi: 10.3389/fendo.2021.616514. eCollection 2021.
7
IDegAsp (insulin degludec + insulin aspart) for the management of type 2 diabetes: current status.德谷门冬胰岛素（胰岛素德谷 + 门冬胰岛素）用于2型糖尿病管理：现状
Expert Rev Endocrinol Metab. 2016 Mar;11(2):103-111. doi: 10.1586/17446651.2016.1145541.
8
The Clinical Role of Insulin Degludec/Insulin Aspart in Type 2 Diabetes: An Empirical Perspective from Experience in Australia.德谷胰岛素/门冬胰岛素在2型糖尿病中的临床作用：来自澳大利亚经验的实证观点
J Clin Med. 2020 Apr 11;9(4):1091. doi: 10.3390/jcm9041091.
9
Practical use of insulin degludec/insulin aspart in a multinational setting: beyond the guidelines.在跨国环境中实际使用德谷胰岛素/门冬胰岛素：超越指南。
Diabetes Obes Metab. 2020 Nov;22(11):1961-1975. doi: 10.1111/dom.14128. Epub 2020 Aug 12.
10
Review of Clinical Profile of IDegAsp.德谷门冬双胰岛素临床概况综述。
J Assoc Physicians India. 2015 May;63(5 Suppl):15-20.
引用本文的文献
1
An Overview of Currently Available Injectable Therapies in Diabetes: A Guide to Practitioners.糖尿病现有注射疗法概述：给从业者的指南
Adv Ther. 2025 Jun 7. doi: 10.1007/s12325-025-03250-3.
2
Stability Convergence in Antibody Coformulations.抗体制剂的稳定性收敛。
Mol Pharm. 2022 Nov 7;19(11):4098-4110. doi: 10.1021/acs.molpharmaceut.2c00534. Epub 2022 Oct 20.
3
Efficacy and Safety of Insulin Degludec/Insulin Aspart (IDegAsp) in Type 2 Diabetes: Systematic Review and Meta-Analysis.德谷胰岛素/门冬胰岛素（IDegAsp）治疗2型糖尿病的疗效与安全性：系统评价和荟萃分析
Cureus. 2022 Jun 2;14(6):e25612. doi: 10.7759/cureus.25612. eCollection 2022 Jun.
4
Real-World Analysis of Rapid-Acting Insulin Analog Use and Its Blood Glucose Lowering Effect in Patients with Type 2 Diabetes Mellitus: Results from PASSION Disease Registry in Korea.2型糖尿病患者速效胰岛素类似物使用情况及其血糖降低效果的真实世界分析：来自韩国PASSION疾病登记处的结果
Diabetes Metab Syndr Obes. 2022 May 11;15:1495-1503. doi: 10.2147/DMSO.S334944. eCollection 2022.
5
Practical guidance on the initiation, titration, and switching of basal insulins: a narrative review for primary care.基础胰岛素起始、滴定和转换的实用指南：基层医疗的叙述性综述。
Ann Med. 2021 Dec;53(1):998-1009. doi: 10.1080/07853890.2021.1925148.
6
Use of Insulin Degludec/Insulin Aspart in the Management of Diabetes Mellitus: Expert Panel Recommendations on Appropriate Practice Patterns.德谷胰岛素/门冬胰岛素在糖尿病管理中的应用：专家小组关于适当实践模式的建议。
Front Endocrinol (Lausanne). 2021 Mar 12;12:616514. doi: 10.3389/fendo.2021.616514. eCollection 2021.
7
Outcomes of transition from premixed and intensive insulin therapies to insulin aspart/degludec co-formulation in type 2 diabetes mellitus: a real-world experience.2型糖尿病患者从预混胰岛素和强化胰岛素治疗转换为门冬胰岛素/德谷胰岛素共混制剂的疗效：一项真实世界研究
Arch Med Sci. 2020 Feb 25;17(1):1-8. doi: 10.5114/aoms.2020.93264. eCollection 2021.
8
Stability enhancement in a mAb and Fab coformulation.单抗和 Fab 共晶体制剂的稳定性增强。
Sci Rep. 2020 Dec 3;10(1):21129. doi: 10.1038/s41598-020-77989-w.
9
Practical use of insulin degludec/insulin aspart in a multinational setting: beyond the guidelines.在跨国环境中实际使用德谷胰岛素/门冬胰岛素：超越指南。
Diabetes Obes Metab. 2020 Nov;22(11):1961-1975. doi: 10.1111/dom.14128. Epub 2020 Aug 12.
10
Choice of Insulin in Type 2 Diabetes: A Southeast Asian Perspective.2型糖尿病胰岛素的选择：东南亚视角
Indian J Endocrinol Metab. 2017 May-Jun;21(3):478-481. doi: 10.4103/ijem.IJEM_82_17.
本文引用的文献
1
The Distinct Prandial and Basal Pharmacodynamics of IDegAsp Observed in Younger Adults Are Preserved in Elderly Subjects with Type 1 Diabetes.在年轻成人中观察到的德谷门冬双胰岛素独特的餐时和基础药效学在老年1型糖尿病患者中得以保留。
Drugs Aging. 2015 Jul;32(7):583-90. doi: 10.1007/s40266-015-0272-y.
2
Distinct Prandial and Basal Glucose-Lowering Effects of Insulin Degludec/Insulin Aspart (IDegAsp) at Steady State in Subjects with Type 1 Diabetes Mellitus.在 1 型糖尿病患者中，德谷胰岛素/门冬胰岛素（IDegAsp）在稳态下具有不同的餐时和基础降糖作用。
Diabetes Ther. 2014 Jun;5(1):255-65. doi: 10.1007/s13300-014-0070-2. Epub 2014 Jun 3.
3
Insulin degludec: a significant advancement in ultralong-acting Basal insulin.德谷胰岛素：超长效基础胰岛素的重大进展。
Diabetes Ther. 2013 Dec;4(2):167-73. doi: 10.1007/s13300-013-0047-6. Epub 2013 Nov 20.
4
A novel insulin combination of insulin degludec and insulin aspart achieves a more stable overnight glucose profile than insulin glargine: results from continuous glucose monitoring in a proof-of-concept trial.德谷胰岛素与门冬胰岛素的新型胰岛素组合在夜间血糖控制方面比甘精胰岛素更稳定：概念验证试验中连续血糖监测的结果。
J Diabetes Sci Technol. 2013 Sep 1;7(5):1328-36. doi: 10.1177/193229681300700524.
5
Exploring insulin analogue safety and effectiveness in a Maghrebian cohort with type 2 diabetes: results from the A₁chieve study.探索 2 型糖尿病马格里布人群中胰岛素类似物的安全性和有效性：A₁chieve 研究结果。
Diabetes Res Clin Pract. 2013 Aug;101 Suppl 1:S4-14. doi: 10.1016/S0168-8227(13)70014-7.
6
Superior glycaemic control with once-daily insulin degludec/insulin aspart versus insulin glargine in Japanese adults with type 2 diabetes inadequately controlled with oral drugs: a randomized, controlled phase 3 trial.在口服药物控制不佳的日本 2 型糖尿病成人中，每日一次德谷胰岛素/门冬胰岛素与甘精胰岛素相比具有更好的血糖控制效果：一项随机对照 3 期试验。
Diabetes Obes Metab. 2013 Sep;15(9):826-32. doi: 10.1111/dom.12097. Epub 2013 Apr 5.
7
Efficacy and safety of insulin degludec in a flexible dosing regimen vs insulin glargine in patients with type 1 diabetes (BEGIN: Flex T1): a 26-week randomized, treat-to-target trial with a 26-week extension.在 1 型糖尿病患者中，灵活剂量方案的胰岛素地特胰岛素与甘精胰岛素的疗效和安全性（BEGIN：Flex T1）：一项 26 周随机、靶向治疗试验及 26 周扩展。
J Clin Endocrinol Metab. 2013 Mar;98(3):1154-62. doi: 10.1210/jc.2012-3249. Epub 2013 Feb 7.
8
The efficacy and safety of insulin degludec given in variable once-daily dosing intervals compared with insulin glargine and insulin degludec dosed at the same time daily: a 26-week, randomized, open-label, parallel-group, treat-to-target trial in individuals with type 2 diabetes.在 26 周的时间内，与甘精胰岛素和每日等量的德谷胰岛素相比，每日不同时间点给予德谷胰岛素的疗效和安全性：一项针对 2 型糖尿病患者的随机、开放标签、平行组、治疗至目标的试验。
Diabetes Care. 2013 Apr;36(4):858-64. doi: 10.2337/dc12-1668. Epub 2013 Jan 22.
9
Insulin degludec versus insulin glargine in insulin-naive patients with type 2 diabetes: a 1-year, randomized, treat-to-target trial (BEGIN Once Long).在 2 型糖尿病的胰岛素初治患者中，德谷胰岛素对比甘精胰岛素：一项为期 1 年、随机、以目标为导向的试验（BEGIN Once Long）。
Diabetes Care. 2012 Dec;35(12):2464-71. doi: 10.2337/dc12-1205. Epub 2012 Oct 5.
10
Insulin degludec/insulin aspart administered once daily at any meal, with insulin aspart at other meals versus a standard basal-bolus regimen in patients with type 1 diabetes: a 26-week, phase 3, randomized, open-label, treat-to-target trial.每日一次在任意一餐中给予德谷胰岛素/门冬胰岛素，其他餐次给予门冬胰岛素，与 1 型糖尿病患者的标准基础-餐时胰岛素方案相比：一项 26 周、3 期、随机、开放标签、以目标为导向的试验。
Diabetes Care. 2012 Nov;35(11):2174-81. doi: 10.2337/dc11-2503. Epub 2012 Aug 28.
Zotero 插件